Sylvain Jereme M 4
4 · DEXCOM INC · Filed Dec 17, 2024
Insider Transaction Report
Form 4
DEXCOM INCDXCM
Sylvain Jereme M
EVP, Chief Financal Officer
Transactions
- Sale
Common Stock
2024-12-16$76.87/sh−744$57,191→ 80,030 total
Footnotes (2)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]Included in this number are 47,625 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025.